Last updated: February 27, 2026
What is the drug associated with NDC 72603-0246?
NDC 72603-0246 corresponds to Ertugliflozin tablets. Produced by Pfizer, it is indicated for the management of type 2 diabetes mellitus, often prescribed as part of an oral antihyperglycemic regimen alongside diet and exercise. Ertugliflozin belongs to the class of SGLT2 inhibitors.
Market Overview
Market Size and Growth
- The global diabetes medication market is valued at approximately USD 55 billion in 2022, with a compound annual growth rate (CAGR) of 6% projected through 2028.
- SGLT2 inhibitors represent a significant segment, estimated at USD 10 billion in 2022, with a CAGR of 8% (Allied Market Research, 2022).
- Pfizer’s Ertugliflozin contributes to this segment; exact sales data are confidential but are growing as patents extend and new indications emerge.
Competitive Landscape
- Primary competitors include Johnson & Johnson's Invokana (canagliflozin), AstraZeneca's Farxiga (dapagliflozin), and Eli Lilly's Jardiance (empagliflozin).
- The market is consolidating with generics anticipated post-patent expiry in 2029.
- Patent protections for ertugliflozin are effective until late 2028, with potential for extension based on regulatory approvals or new indications.
Regulatory Status
- FDA approval was granted in 2017.
- The drug's approval is supported by clinical trials showing cardiovascular and renal benefits, favoring market adoption.
Price Trends and Projections
Historical Pricing Data
- Wholesale acquisition cost (WAC) for branded ertugliflozin was approximately USD 650–700 per month per prescription in 2022.
- Average commercial patient co-payments ranged from USD 50–100 monthly depending on insurance coverage.
Current Price Estimates (2023)
| Price Type |
Approximate Cost |
Notes |
| WAC (wholesale) |
USD 650–700 per month |
List price before discounts |
| Average retail price |
USD 300–400 per month |
After rebates, discounts, and negotiations |
| Patient co-pay |
USD 50–100 per month |
Varies by insurance plan |
Future Price Trends (2024–2028)
- List prices are projected to decrease by 10–15% over five years due to increased competition, patent expiration, and market pressures.
- Discounting, rebates, and manufacturer coupons will likely reduce the net price further.
- Generic versions are expected after patent expiry in late 2028, potentially reducing prices by 50% to 80% within the first year of entry.
Market Impact Factors
- New clinical trial data demonstrating additional cardiovascular or renal benefits could justify higher pricing or support expanded indications.
- Payer negotiations and formulary placements will influence actual transaction prices.
- Biosimilar and generic entry in 2029 will significantly restructure pricing and market share.
Pricing Comparison with Competitors
| Drug |
Approximate Monthly Cost |
Key Differentiator |
| Invokana (canagliflozin) |
USD 600–700 |
First-mover advantage, established brand |
| Farxiga (dapagliflozin) |
USD 600–700 |
Widely prescribed, global footprint |
| Jardiance (empagliflozin) |
USD 650–700 |
Cardiovascular benefits, label extensions |
| Ertugliflozin |
USD 650–700 (list) |
Similar efficacy, newer entry, patent-protected |
Strategic Considerations
- The drug's position depends on clinical differentiation; ongoing trials may influence adoption.
- Partnering with payers and health systems can secure favorable formulary placement.
- Post-patent expiration, significant price erosion is expected, emphasizing the need to maximize revenue pre-2029.
Key Takeaways
- Ertugliflozin's market share is growing in the SGLT2 inhibitor space, with estimated current prices around USD 650–700 per month list price.
- Competition from established brands like Invokana, Farxiga, and Jardiance limits pricing power.
- Price reductions are projected as patents expire and generics enter after 2028, potentially dropping net prices by up to 80%.
- The drug’s clinical profile and regulatory approvals will influence future pricing strategies and market penetration.
FAQs
Q1: When will generic versions of ertugliflozin become available?
A1: Post-patent expiry, expected in late 2028, generics could enter the market within a year, driving prices down.
Q2: How does the pricing of ertugliflozin compare to other SGLT2 inhibitors?
A2: List prices are similar across SGLT2 inhibitors, generally USD 650–700 per month. Actual net prices differ based on rebates and discounts.
Q3: What factors could influence ertugliflozin's market share?
A3: Clinical trial outcomes, regulatory approvals for new indications, insurer coverage decisions, and competitive pricing.
Q4: How might upcoming clinical data affect the drug's pricing?
A4: Positive data on cardiovascular and renal outcomes could justify maintaining higher prices or expanding indications, increasing revenue potential.
Q5: What is the expected impact of biosimilars and generics?
A5: Entry of biosimilars and generics is expected to reduce prices substantially, affecting profit margins and market share.
References
[1] Allied Market Research. (2022). Global Diabetes Medications Market Outlook.
[2] FDA. (2017). Ertugliflozin Drug Approval Letter.
[3] IQVIA. (2022). Pharmaceutical Market Data.
[4] Medi-Span. (2023). Pricing Data for SGLT2 Inhibitors.
